glp 1 drugs and ms A Phase 2 trial just began testing whether a GLP-1 drug can slow brain shrinkage Episode 444: A GLP-1 Drug
Description
Available from: Collins L, Costello RA
Ready to take the next step
GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl peptidase-4 inhibitors, according to findings scheduled for presentation at ASCO Annual Meeting
Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes
Estimation of primary prevention of gout in men through modification of obesity and other key lifestyle factors
95% CI, 0.61-3.63 and RR, 1.92
